TRex Bio develops immunoregulatory therapies targeting autoimmune and inflammatory conditions globally. The company operates proprietary platforms for drug discovery that leverage regulatory T cell biology and computational tools to identify and validate therapeutic targets, along with high-throughput assays to test candidate compounds. Its pipeline includes multiple investigational programs at varying stages, such as agonists designed to activate regulatory T cells in inflamed tissues for conditions including inflammatory bowel disease and lupus.

entry readiness 42 · WEAK SETUP · exit proximity 0